November 23, 2019 : Issue #1017

TOP STORIES — Diabetes News and Research

Canagliflozin’s Efficacy and Safety For Delaying and Possibly Preventing ESKD

Head-to-Head Comparison: Oral Semaglutide vs. Empagliflozin

Improving Diabetes Outcomes: Collaborative Patient Care in a New Multispecialty MSO Model

by Guest Writer Richard Purcell

Last week I mentioned the problems with the TZD’s and cardiovascular health. The uproar that this correlation had was enough to cause the FDA to require cardiovascular studies on all new and future diabetes medications. Many times the pharma companies looked at these studies as an unnecessary hindrance to bringing a new drug to market. However, when it came to the SGLT-2 inhibitors, I am guessing that every one of the companies were happy they had to do the studies and learn the CV positive benefits they could talk about.

This week our Intern, Andrew Daoud, PharmD Candidate, Florida A&M University, has some information on another claim that one of the products can make, that can be life-saving for many of our patients. Click here to find out what the drug is and what its new indication is for. 

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Kidney failure is an enormous concern for people with T2D and DKD. This analysis confirms canagliflozin can slow its progression and have an impact on patients regardless of their level of kidney function.

The first oral glucagon-like peptide receptor agonist recently gained FDA approval, but how does it compare to oral agents already on the market?

by Guest Writer Richard Purcell
More than 100 million U.S. adults are now living with diabetes or prediabetes, according to the Centers for Disease Control and Prevention.1 This epidemic requires new healthcare models to deliver optimal, patient-focused, guideline-directed care to improve outcomes and reduce costs. The establishment of a new multispecialty Managed Services Organization (MSO) in Arizona spotlights the numerous benefits, to patients and providers alike, of providing end-to-end healthcare services and disease management solutions for complex diabetes.

Americans take a serious hit from the treatment of their diabetes.  Treating type 1 and type 2 diabetes cost $327 billion in 2017, according to a study commissioned by the ADA. The figure represents a concerning 26 percent increase from the previous estimate of $245 billion, which used data from 2012.

Of that total, $237 billion is attributed to direct medical expenses, the ADA says. Major contributors to that number are hospital inpatient care and prescription medications, each of which accounted for 30 percent of direct spending.  Antidiabetic agents and diabetic-specific supplies represent 15 percent of costs, and visits to the physician’s office added up to account for 13 percent. But the buck doesn’t stop there. Diabetes costs the U.S. economy another $90 billion from lost economic productivity, according to the study. Sources of the deficit caused by diabetic complications include absenteeism, reduced productivity at work, inability to work and early mortality.

People with diagnosed diabetes incur average medical expenditures of $16,752 per year, according to the ADA. “On average. people with diagnosed diabetes have medical expenditures approximately 2.3 times higher than what expenditures would be in the absence of diabetes.” This monetary cost, while staggering, only tells a small part of the story. According to 2015 data, the ADA estimates that 76 percent of more than 30 million Americans with diabetes are not diagnosed, which means that about 7 million Americans’ healthcare costs are outside the scope of its report.  The study also cannot account for the qualitative effects of the disease, as the ADA notes. Dental, podiatric, cardiovascular, dermatologic issues, and viral and bacterial infections due to the reduced ability to fight off infections are also not included costs also are not included. Other societal costs add to the financial burden, such as factors from pain and suffering, resources from care provided by non-paid caregivers and the burden associated with undiagnosed diabetes.

With another 90-100 million people with prediabetes, the future looks bleak.

JAMA Netw Open. 2019;2(11):e1915360. doi:10.1001/jamanetworkopen.2019.15360Advances in Nutrition, Volume 5, Issue 1, January 2014, Pages 7–15, https://doi.org/10.3945/an.113.004929

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Jordan Boyd, PharmD. Candidate Florida Agricultural & Mechanical University School of Pharmacy

Andrew Daoud, PharmD Candidate, Florida A&M University

Usif Darwish, PharmD Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences

Hira Gohar, Florida A&M University, College of Pharmacy, PharmD Candidate

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.